Home » Stocks » Sonnet BioTherapeutics

Sonnet BioTherapeutics Holdings, Inc. (SONN)

Stock Price: $2.61 USD -0.07 (-2.61%)
Updated Sep 22, 2020 11:18 AM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 35.61M
Revenue (ttm) 14.92M
Net Income (ttm) -26.34M
Shares Out 13.64M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Sep 22, 2020
Last Price $2.61
Previous Close $2.68
Change ($) -0.07
Change (%) -2.61%
Day's Open 2.62
Day's Range 2.55 - 2.66
Day's Volume 526,461
52-Week Range 2.32 - 54.60

More Stats

Market Cap 35.61M
Enterprise Value 32.88M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 13.64M
Float 11.78M
EPS (basic) n/a
EPS (diluted) n/a
FCF / Share -1.14
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 556,272
Short Ratio 0.09
Short % of Float 0.00%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 2.39
PB Ratio 93.76
Revenue 14.92M
Operating Income -24.51M
Net Income -26.34M
Free Cash Flow -12.80M
Net Cash 2.73M
Net Cash / Share 0.20
Gross Margin n/a
Operating Margin -164.30%
Profit Margin -177.10%
FCF Margin -85.82%
ROA n/a
ROE n/a
ROIC -233.20%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (1)

Buy 1
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$8.00*
Low
8.00
Current: $2.61
High
8.00
Target: 8.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue30.1430.7341.4341.7035.3529.848.256.851.480.14
Revenue Growth-1.92%-25.82%-0.65%17.96%18.46%261.85%20.36%364.05%983.37%-
Gross Profit1.242.614.315.673.922.550.310.310.370.14
Operating Income-16.08-5.37-5.24-2.62-5.08-5.54-4.61-2.59-0.96-1.06
Net Income-17.73-6.85-6.79-9.08-12.14-6.40-5.21-3.17-1.16-1.01
Shares Outstanding0.270.140.100.080.050.020.020.01--
Earnings Per Share-66.56-51.48-70.98-108.68-221.01-265.21-312.01-325.01-254.81-265.21
Operating Cash Flow-4.05-1.11-0.72-0.51-5.25-1.03-2.70-2.38-1.16-0.76
Capital Expenditures-0.47-1.70-1.16-1.18-1.80-1.97-3.66-1.17-0.22-
Free Cash Flow-4.52-2.81-1.89-1.69-7.05-3.00-6.36-3.55-1.38-0.76
Cash & Equivalents0.500.520.440.271.220.250.441.220.170.05
Total Debt24.319.668.9510.169.358.821.820.323.160.94
Net Cash / Debt-23.81-9.14-8.52-9.89-8.12-8.57-1.370.90-3.00-0.89
Assets31.5329.7930.1833.4942.2135.7920.097.654.801.41
Liabilities34.6821.5418.6919.7820.4520.828.852.124.311.33
Book Value-3.617.4310.7112.5621.3710.0710.845.46-0.110.06
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Sonnet BioTherapeutics Holdings, Inc.
Country United States
Employees 30
CEO Pankaj Mohan

Stock Information

Ticker Symbol SONN
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: SONN

Description

SONNET BioTherapeutics, Inc. is a biotechnology company that engages in development of bi and tri functional therapies that can simulate or block immune-modulating targets to control cancer. The company uses albumin binding single chain antibody fragment (scFv) for delivery of recombinant human-cytokines (rH-cytokines) and other validated targets. SONNET BioTherapeutics, Inc. was incorporated in 2015 and is based in Princeton, New Jersey.